VolitionRx hits milestone in Nu.Q Capture blood-based cancer-detection technology
VolitionRx Limited (NYSEAMERICAN:VNRX) has achieved a major milestone in the development of its Nu.Q Capture cancer-detection technology: the ability to enrich nucleosomes.
Nu.Q works by measuring circulating nucleosomes in the blood, irregular levels of which are associated with cancer. By enriching them, Volition can determine whether the origin of particular DNA is tumor or non-tumor.
The potential uses are twofold, the company said. First, it can heighten the specificity of Volition’s screenings by removing that background signal. Second, it can be used to enrich nucleosomes of cancer origin in sequencing-based liquid biopsies, a cancer diagnostic technique.
READ: VolitionRx balance sheet strengthens in second quarter with cash increasing significantly
“I am extremely excited that this enabling technology could bridge the gap between Volition’s epigenetic profiling approach to early detection and those sequencing approaches that have so far been limited to personalized treatment selection,” Business Development Director Mark Eccleston said in a statement.
Last week, the company filed for a patent for intellectual property related to Nu.Q capture.
Now, Eccleston said, the company is working to determine the level of discrimination of tumor-derived nucleosomes in order to provide a complete analysis of nucleosomes in the blood.
A nucleosome is a segment of DNA coiled around a protein core. Nucleosomes that end up outside of cells and in the bloodstream are known as cell-free nucleosomes, which Volition uses in its screenings.
Chief Scientific Officer Jake Micallef said the company has hit a breakthrough after nearly a decade in epigenetics, which studies the effects of modifying gene expression.
“Volition is focused on advancing the science of epigenetics and has developed an extensive understanding of chromosome and nucleosome structures, particularly in blood.” Micallef said in a statement. “I believe all the work we have done over the past 9 years [...] puts us at the cutting edge of epigenetics.”
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/902877/volitionrx-hits-milestone-in-nuq-capture-blood-based-cancer-detection-technology-902877.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).